Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

FAYUVI is presented as a potential first-ever treatment for Sanfilippo syndrome Type A, a rare neurodegenerative condition with irreversible loss of function. The treatment could stop or slow disease progression, though the article provides no clinical-trial data, regulatory status, pricing, or commercial outlook.